• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Increased albumin infusions did not improve decompensated cirrhosis

byConstance Wu
March 17, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Administration of human albumin solution was shown not to lead to any clinical improvement in patients hospitalized with cirrhosis.

2. The albumin group had more serious adverse events such as pulmonary edema or fluid overload compared to the standard of care group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Liver cirrhosis is one of the leading causes of death, where decompensated disease can even lead to kidney failure and death. However, large-scale clinical studies regarding albumin infusions and the benefit of increased serum albumin levels have yet to be conducted. This trial examined human albumin solution administration to hospitalized patients with decompensated cirrhosis. The study concluded targeted albumin therapy had no added benefits or clinical significance in the treatment group when compared to the control group. Moreover, more serious adverse events were noted in the treatment group compared to the control group. Patients in this study were not blinded to which treatment they were receiving, therefore, limiting the study. Nonetheless, this study’s results indicate significant findings since infections and other adverse events were not prevented as a result of increased serum albumin.

Click to read the study in NEJM

Relevant Reading: The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology

In-Depth [randomized controlled trial]: This randomized control trial was conducted across multiple sites in the United Kingdom where a total of 777 hospitalized patients were enrolled in the study. Patients 18 years of age or older diagnosed with decompensated cirrhosis, presenting with acute complications, and a serum albumin level of less than 30g/L within 72 hours of admission were included in the study. Patients likely to be discharged prior to 5 days were excluded from the study. Patients were randomized to the standard of care group or the albumin group. The primary endpoint of the study was to assess adverse events including death between days 3 and 15 of recruitment. Patients in the albumin group displayed blood serum albumin levels of 30g/L or more by Day 3. Within the albumin group, 113 of 380 (29.7%) patients displayed the primary endpoint compared to 120 of 397 (30.2%) patients in the standard of care group (adjusted odds ratio, 0.98; 95% confidence interval [CI], 0.71 to 1.33; P=0.87). Furthermore, severe and life-threatening events were observed more in the albumin group versus the standard of care groups such as pulmonary edema, gastrointestinal bleeding, and even death. Overall, the study revealed no added benefits of receiving human albumin transfusion in patients hospitalized with decompensated cirrhosis.

RELATED REPORTS

OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]

Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency

The Milan Criteria: Liver transplantation is effective for treating cirrhotic patients with unrespectable hepatocellular carcinomas [Classics Series]

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: albumincirrhosisdecompensated cirrhosisliver transplant
Previous Post

PICU admissions due to bronchiolitis markedly reduced during COVID-19 pandemic

Next Post

Sex differences in ischemic stroke outcomes in patients with pulmonary hypertension

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]

June 30, 2022
Novel combination therapy may be effective for noncirrhotic HCV infection [UNITY-1 trial]
Chronic Disease

Fazirsiran reduces Z-AAT protein production in alpha1-antitrypsin deficiency

June 29, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

The Milan Criteria: Liver transplantation is effective for treating cirrhotic patients with unrespectable hepatocellular carcinomas [Classics Series]

June 28, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
General Medicine Classics

The Child-Pugh score: Prognosis in chronic liver disease and cirrhosis [Classics Series]

December 3, 2021
Next Post
Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial

Sex differences in ischemic stroke outcomes in patients with pulmonary hypertension

Physical therapy reduces pain in adults with knee osteoarthritis

Telephone cognitive behavioral therapy for insomnia in adults With osteoarthritis pain

Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress

Donanemab improved cognitive measures in early Alzheimer’s disease

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.